Paratek Pharmaceuticals Stock Beta
Paratek Pharmaceuticals fundamentals help investors to digest information that contributes to Paratek Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Paratek Stock. The fundamental analysis module provides a way to measure Paratek Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Paratek Pharmaceuticals stock.
Paratek |
Paratek Pharmaceuticals Company Beta Analysis
Paratek Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Paratek Pharmaceuticals Beta | 1.7 |
Most of Paratek Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Paratek Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Paratek Pharmaceuticals has a Beta of 1.6978. This is 97.42% higher than that of the Pharmaceuticals sector and 22.14% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Paratek Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Paratek Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Paratek Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Paratek Pharmaceuticals by comparing valuation metrics of similar companies.Paratek Pharmaceuticals is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Paratek Pharmaceuticals will likely underperform.
Paratek Fundamentals
| Return On Asset | -0.18 | |||
| Profit Margin | (0.35) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 345.3 M | |||
| Shares Outstanding | 57.32 M | |||
| Shares Owned By Insiders | 11.70 % | |||
| Shares Owned By Institutions | 55.08 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Earning | (5.49) X | |||
| Price To Sales | 0.86 X | |||
| Revenue | 150.79 M | |||
| Gross Profit | 99.39 M | |||
| EBITDA | (44.9 M) | |||
| Net Income | (63.57 M) | |||
| Cash And Equivalents | 57.01 M | |||
| Cash Per Share | 1.03 X | |||
| Total Debt | 258.41 M | |||
| Debt To Equity | 3.20 % | |||
| Current Ratio | 3.11 X | |||
| Book Value Per Share | (3.52) X | |||
| Cash Flow From Operations | (66.14 M) | |||
| Short Ratio | 6.74 X | |||
| Earnings Per Share | (1.11) X | |||
| Price To Earnings To Growth | (0.02) X | |||
| Target Price | 3.1 | |||
| Number Of Employees | 268 | |||
| Beta | 1.7 | |||
| Market Capitalization | 127.83 M | |||
| Total Asset | 172.54 M | |||
| Retained Earnings | (930.45 M) | |||
| Working Capital | 99.45 M | |||
| Current Asset | 127.46 M | |||
| Current Liabilities | 21.75 M | |||
| Z Score | -6.55 | |||
| Net Asset | 172.54 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |